HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Warns PhytoCeuticals For Adulterated Cosmetics, Cancer Claims

This article was originally published in The Rose Sheet

Executive Summary

Agency’s most recently posted warning letters to skin-care marketers include one to PhytoCeuticals for adulterated cosmetics, following an inspection of the company’s manufacturing facility. Osea Internacional and Face Naturals also draw warnings for claims that identify their products as unapproved drugs.

You may also be interested in...

ASA: Olay Regenerist 'Cell By Cell' Exfoliation Claims Imply 'Physiological' Effects

Ads claiming P&G's Olay Regenerist skin-care line “re-energizes skin’s appearance cell by cell” mislead consumers into expecting deeper cellular changes rather than mere surface exfoliation, an implied benefit unsupported by the firm's evidence, according to the UK’s independent regulator.

FDA Scorches Sunscreen Wipe Marketers With October Warning Letters

Inspections conducted over the past year may have contributed to a wider FDA crackdown on unapproved sunscreen drug products – specifically those in dosage forms deemed ineligible under OTC drug review for inclusion in the sunscreen monograph – with five marketers targeted so far this month with warning letters.

‘Ant-type Insects’ And Expired Ingredients: FDA Warns Bioque Following Inspection

Agency inspectors observed a range of insanitary conditions and practices at the Blacksburg, Virginia-based manufacturing site that turns out Bioque and Vouray skin-care products, causing the products to be adulterated, according to an FDA warning letter.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts